nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ALB—Auranofin—psoriatic arthritis	0.251	0.27	CbGbCtD
Canagliflozin—ABCC2—Dexamethasone—psoriatic arthritis	0.0801	0.0861	CbGbCtD
Canagliflozin—ALB—Prednisone—psoriatic arthritis	0.08	0.086	CbGbCtD
Canagliflozin—ABCB1—Methylprednisolone—psoriatic arthritis	0.0691	0.0742	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—psoriatic arthritis	0.0644	0.0692	CbGbCtD
Canagliflozin—ABCB1—Betamethasone—psoriatic arthritis	0.0449	0.0483	CbGbCtD
Canagliflozin—ABCB1—Prednisolone—psoriatic arthritis	0.0443	0.0476	CbGbCtD
Canagliflozin—ABCB1—Prednisone—psoriatic arthritis	0.0418	0.045	CbGbCtD
Canagliflozin—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0414	0.0445	CbGbCtD
Canagliflozin—ALB—Methotrexate—psoriatic arthritis	0.0401	0.0431	CbGbCtD
Canagliflozin—CYP3A4—Triamcinolone—psoriatic arthritis	0.0314	0.0337	CbGbCtD
Canagliflozin—CYP3A4—Betamethasone—psoriatic arthritis	0.0269	0.0289	CbGbCtD
Canagliflozin—CYP3A4—Prednisolone—psoriatic arthritis	0.0265	0.0285	CbGbCtD
Canagliflozin—ABCB1—Dexamethasone—psoriatic arthritis	0.0261	0.0281	CbGbCtD
Canagliflozin—CYP3A4—Prednisone—psoriatic arthritis	0.0251	0.027	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—psoriatic arthritis	0.021	0.0226	CbGbCtD
Canagliflozin—CYP3A4—Dexamethasone—psoriatic arthritis	0.0156	0.0168	CbGbCtD
Canagliflozin—Blood potassium increased—Prednisone—psoriatic arthritis	0.00215	0.0307	CcSEcCtD
Canagliflozin—Sunburn—Methotrexate—psoriatic arthritis	0.0018	0.0257	CcSEcCtD
Canagliflozin—Multiple fractures—Methylprednisolone—psoriatic arthritis	0.00141	0.0202	CcSEcCtD
Canagliflozin—Fracture—Methylprednisolone—psoriatic arthritis	0.00141	0.0202	CcSEcCtD
Canagliflozin—Multiple fractures—Dexamethasone—psoriatic arthritis	0.00128	0.0183	CcSEcCtD
Canagliflozin—Fracture—Betamethasone—psoriatic arthritis	0.00128	0.0183	CcSEcCtD
Canagliflozin—Fracture—Dexamethasone—psoriatic arthritis	0.00128	0.0183	CcSEcCtD
Canagliflozin—Multiple fractures—Betamethasone—psoriatic arthritis	0.00128	0.0183	CcSEcCtD
Canagliflozin—Angioedema—Auranofin—psoriatic arthritis	0.00112	0.016	CcSEcCtD
Canagliflozin—Fracture—Prednisone—psoriatic arthritis	0.00112	0.016	CcSEcCtD
Canagliflozin—Multiple fractures—Prednisone—psoriatic arthritis	0.00112	0.016	CcSEcCtD
Canagliflozin—Rash erythematous—Dexamethasone—psoriatic arthritis	0.000974	0.0139	CcSEcCtD
Canagliflozin—Rash erythematous—Betamethasone—psoriatic arthritis	0.000974	0.0139	CcSEcCtD
Canagliflozin—Fracture—Methotrexate—psoriatic arthritis	0.000934	0.0133	CcSEcCtD
Canagliflozin—Multiple fractures—Methotrexate—psoriatic arthritis	0.000934	0.0133	CcSEcCtD
Canagliflozin—Constipation—Auranofin—psoriatic arthritis	0.000855	0.0122	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Auranofin—psoriatic arthritis	0.000818	0.0117	CcSEcCtD
Canagliflozin—Urticaria—Auranofin—psoriatic arthritis	0.000794	0.0114	CcSEcCtD
Canagliflozin—Abdominal pain—Auranofin—psoriatic arthritis	0.00079	0.0113	CcSEcCtD
Canagliflozin—Diabetes mellitus—Prednisolone—psoriatic arthritis	0.000746	0.0107	CcSEcCtD
Canagliflozin—Pruritus—Auranofin—psoriatic arthritis	0.000707	0.0101	CcSEcCtD
Canagliflozin—Diabetes mellitus—Triamcinolone—psoriatic arthritis	0.000686	0.0098	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methylprednisolone—psoriatic arthritis	0.000684	0.00978	CcSEcCtD
Canagliflozin—Rash—Auranofin—psoriatic arthritis	0.00063	0.00901	CcSEcCtD
Canagliflozin—Dermatitis—Auranofin—psoriatic arthritis	0.00063	0.009	CcSEcCtD
Canagliflozin—Diabetes mellitus—Betamethasone—psoriatic arthritis	0.000622	0.00889	CcSEcCtD
Canagliflozin—Diabetes mellitus—Dexamethasone—psoriatic arthritis	0.000622	0.00889	CcSEcCtD
Canagliflozin—Nausea—Auranofin—psoriatic arthritis	0.000594	0.00849	CcSEcCtD
Canagliflozin—Pancreatitis—Prednisolone—psoriatic arthritis	0.00055	0.00785	CcSEcCtD
Canagliflozin—Diabetes mellitus—Prednisone—psoriatic arthritis	0.000542	0.00774	CcSEcCtD
Canagliflozin—Breast disorder—Methylprednisolone—psoriatic arthritis	0.000538	0.00769	CcSEcCtD
Canagliflozin—Cystitis noninfective—Methotrexate—psoriatic arthritis	0.00053	0.00757	CcSEcCtD
Canagliflozin—Cystitis—Methotrexate—psoriatic arthritis	0.000524	0.00749	CcSEcCtD
Canagliflozin—Vaginal infection—Methotrexate—psoriatic arthritis	0.000512	0.00732	CcSEcCtD
Canagliflozin—Pancreatitis—Triamcinolone—psoriatic arthritis	0.000505	0.00722	CcSEcCtD
Canagliflozin—Pancreatitis—Methylprednisolone—psoriatic arthritis	0.000504	0.00721	CcSEcCtD
Canagliflozin—Bladder pain—Methotrexate—psoriatic arthritis	0.000491	0.00701	CcSEcCtD
Canagliflozin—Urine output increased—Methotrexate—psoriatic arthritis	0.000491	0.00701	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methotrexate—psoriatic arthritis	0.000453	0.00647	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—psoriatic arthritis	0.000449	0.00641	CcSEcCtD
Canagliflozin—Polyuria—Methotrexate—psoriatic arthritis	0.000449	0.00641	CcSEcCtD
Canagliflozin—Renal failure acute—Methotrexate—psoriatic arthritis	0.000427	0.0061	CcSEcCtD
Canagliflozin—Pancreatitis—Prednisone—psoriatic arthritis	0.000399	0.00571	CcSEcCtD
Canagliflozin—Erythema—Prednisolone—psoriatic arthritis	0.000391	0.00558	CcSEcCtD
Canagliflozin—Angiopathy—Methylprednisolone—psoriatic arthritis	0.000374	0.00534	CcSEcCtD
Canagliflozin—Erythema—Triamcinolone—psoriatic arthritis	0.000359	0.00513	CcSEcCtD
Canagliflozin—Erythema—Methylprednisolone—psoriatic arthritis	0.000358	0.00512	CcSEcCtD
Canagliflozin—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000358	0.00512	CcSEcCtD
Canagliflozin—Angioedema—Prednisolone—psoriatic arthritis	0.000357	0.0051	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—psoriatic arthritis	0.000356	0.00509	CcSEcCtD
Canagliflozin—Syncope—Prednisolone—psoriatic arthritis	0.00035	0.00501	CcSEcCtD
Canagliflozin—Loss of consciousness—Prednisolone—psoriatic arthritis	0.000343	0.00491	CcSEcCtD
Canagliflozin—Angiopathy—Betamethasone—psoriatic arthritis	0.00034	0.00485	CcSEcCtD
Canagliflozin—Angiopathy—Dexamethasone—psoriatic arthritis	0.00034	0.00485	CcSEcCtD
Canagliflozin—Convulsion—Prednisolone—psoriatic arthritis	0.000338	0.00484	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—psoriatic arthritis	0.000334	0.00477	CcSEcCtD
Canagliflozin—Angioedema—Triamcinolone—psoriatic arthritis	0.000328	0.00469	CcSEcCtD
Canagliflozin—Angioedema—Methylprednisolone—psoriatic arthritis	0.000327	0.00468	CcSEcCtD
Canagliflozin—Erythema—Betamethasone—psoriatic arthritis	0.000326	0.00466	CcSEcCtD
Canagliflozin—Erythema—Dexamethasone—psoriatic arthritis	0.000326	0.00466	CcSEcCtD
Canagliflozin—Syncope—Triamcinolone—psoriatic arthritis	0.000322	0.0046	CcSEcCtD
Canagliflozin—Syncope—Methylprednisolone—psoriatic arthritis	0.000321	0.00459	CcSEcCtD
Canagliflozin—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.000316	0.00451	CcSEcCtD
Canagliflozin—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.000315	0.0045	CcSEcCtD
Canagliflozin—Shock—Prednisolone—psoriatic arthritis	0.000314	0.00448	CcSEcCtD
Canagliflozin—Convulsion—Triamcinolone—psoriatic arthritis	0.000311	0.00445	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—psoriatic arthritis	0.000311	0.00444	CcSEcCtD
Canagliflozin—Convulsion—Methylprednisolone—psoriatic arthritis	0.000311	0.00444	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000303	0.00433	CcSEcCtD
Canagliflozin—Dry mouth—Triamcinolone—psoriatic arthritis	0.000299	0.00427	CcSEcCtD
Canagliflozin—Angioedema—Betamethasone—psoriatic arthritis	0.000298	0.00426	CcSEcCtD
Canagliflozin—Angioedema—Dexamethasone—psoriatic arthritis	0.000298	0.00426	CcSEcCtD
Canagliflozin—Angiopathy—Prednisone—psoriatic arthritis	0.000296	0.00423	CcSEcCtD
Canagliflozin—Syncope—Dexamethasone—psoriatic arthritis	0.000292	0.00418	CcSEcCtD
Canagliflozin—Syncope—Betamethasone—psoriatic arthritis	0.000292	0.00418	CcSEcCtD
Canagliflozin—Infection—Triamcinolone—psoriatic arthritis	0.000291	0.00416	CcSEcCtD
Canagliflozin—Infection—Methylprednisolone—psoriatic arthritis	0.000291	0.00415	CcSEcCtD
Canagliflozin—Shock—Triamcinolone—psoriatic arthritis	0.000288	0.00412	CcSEcCtD
Canagliflozin—Shock—Methylprednisolone—psoriatic arthritis	0.000288	0.00411	CcSEcCtD
Canagliflozin—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000287	0.0041	CcSEcCtD
Canagliflozin—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000286	0.00409	CcSEcCtD
Canagliflozin—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000286	0.00409	CcSEcCtD
Canagliflozin—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000284	0.00406	CcSEcCtD
Canagliflozin—Erythema—Prednisone—psoriatic arthritis	0.000284	0.00406	CcSEcCtD
Canagliflozin—Malnutrition—Prednisone—psoriatic arthritis	0.000284	0.00406	CcSEcCtD
Canagliflozin—Convulsion—Betamethasone—psoriatic arthritis	0.000282	0.00404	CcSEcCtD
Canagliflozin—Convulsion—Dexamethasone—psoriatic arthritis	0.000282	0.00404	CcSEcCtD
Canagliflozin—Hypotension—Methylprednisolone—psoriatic arthritis	0.000273	0.00391	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000269	0.00385	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—psoriatic arthritis	0.000267	0.00382	CcSEcCtD
Canagliflozin—Infection—Betamethasone—psoriatic arthritis	0.000264	0.00378	CcSEcCtD
Canagliflozin—Infection—Dexamethasone—psoriatic arthritis	0.000264	0.00378	CcSEcCtD
Canagliflozin—Shock—Betamethasone—psoriatic arthritis	0.000262	0.00374	CcSEcCtD
Canagliflozin—Shock—Dexamethasone—psoriatic arthritis	0.000262	0.00374	CcSEcCtD
Canagliflozin—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000261	0.00373	CcSEcCtD
Canagliflozin—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000261	0.00373	CcSEcCtD
Canagliflozin—Angioedema—Prednisone—psoriatic arthritis	0.000259	0.00371	CcSEcCtD
Canagliflozin—Syncope—Prednisone—psoriatic arthritis	0.000255	0.00364	CcSEcCtD
Canagliflozin—Urticaria—Prednisolone—psoriatic arthritis	0.000253	0.00362	CcSEcCtD
Canagliflozin—Fatigue—Triamcinolone—psoriatic arthritis	0.000253	0.00361	CcSEcCtD
Canagliflozin—Fatigue—Methylprednisolone—psoriatic arthritis	0.000252	0.0036	CcSEcCtD
Canagliflozin—Loss of consciousness—Prednisone—psoriatic arthritis	0.000249	0.00357	CcSEcCtD
Canagliflozin—Hypotension—Dexamethasone—psoriatic arthritis	0.000249	0.00355	CcSEcCtD
Canagliflozin—Hypotension—Betamethasone—psoriatic arthritis	0.000249	0.00355	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—psoriatic arthritis	0.000247	0.00353	CcSEcCtD
Canagliflozin—Convulsion—Prednisone—psoriatic arthritis	0.000246	0.00351	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.00024	0.00343	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000239	0.00342	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—psoriatic arthritis	0.000237	0.00339	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—psoriatic arthritis	0.000237	0.00339	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000235	0.00336	CcSEcCtD
Canagliflozin—Urticaria—Triamcinolone—psoriatic arthritis	0.000233	0.00333	CcSEcCtD
Canagliflozin—Urticaria—Methylprednisolone—psoriatic arthritis	0.000232	0.00332	CcSEcCtD
Canagliflozin—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000231	0.0033	CcSEcCtD
Canagliflozin—Infection—Prednisone—psoriatic arthritis	0.00023	0.00329	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00023	0.00328	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00023	0.00328	CcSEcCtD
Canagliflozin—Fatigue—Dexamethasone—psoriatic arthritis	0.000229	0.00328	CcSEcCtD
Canagliflozin—Fatigue—Betamethasone—psoriatic arthritis	0.000229	0.00328	CcSEcCtD
Canagliflozin—Shock—Prednisone—psoriatic arthritis	0.000228	0.00326	CcSEcCtD
Canagliflozin—Nervous system disorder—Prednisone—psoriatic arthritis	0.000227	0.00325	CcSEcCtD
Canagliflozin—Skin disorder—Prednisone—psoriatic arthritis	0.000225	0.00322	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000217	0.00311	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000217	0.00311	CcSEcCtD
Canagliflozin—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000216	0.00309	CcSEcCtD
Canagliflozin—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000215	0.00308	CcSEcCtD
Canagliflozin—Urticaria—Dexamethasone—psoriatic arthritis	0.000211	0.00302	CcSEcCtD
Canagliflozin—Urticaria—Betamethasone—psoriatic arthritis	0.000211	0.00302	CcSEcCtD
Canagliflozin—Dizziness—Prednisolone—psoriatic arthritis	0.000211	0.00301	CcSEcCtD
Canagliflozin—Asthenia—Triamcinolone—psoriatic arthritis	0.00021	0.00301	CcSEcCtD
Canagliflozin—Abdominal pain—Betamethasone—psoriatic arthritis	0.00021	0.003	CcSEcCtD
Canagliflozin—Abdominal pain—Dexamethasone—psoriatic arthritis	0.00021	0.003	CcSEcCtD
Canagliflozin—Asthenia—Methylprednisolone—psoriatic arthritis	0.00021	0.003	CcSEcCtD
Canagliflozin—Pruritus—Triamcinolone—psoriatic arthritis	0.000207	0.00296	CcSEcCtD
Canagliflozin—Pruritus—Methylprednisolone—psoriatic arthritis	0.000207	0.00296	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—psoriatic arthritis	0.000206	0.00294	CcSEcCtD
Canagliflozin—Rash—Prednisolone—psoriatic arthritis	0.000201	0.00287	CcSEcCtD
Canagliflozin—Dermatitis—Prednisolone—psoriatic arthritis	0.000201	0.00287	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000201	0.00287	CcSEcCtD
Canagliflozin—Fatigue—Prednisone—psoriatic arthritis	0.0002	0.00285	CcSEcCtD
Canagliflozin—Constipation—Prednisone—psoriatic arthritis	0.000198	0.00283	CcSEcCtD
Canagliflozin—Dizziness—Triamcinolone—psoriatic arthritis	0.000194	0.00277	CcSEcCtD
Canagliflozin—Dizziness—Methylprednisolone—psoriatic arthritis	0.000193	0.00276	CcSEcCtD
Canagliflozin—Infection—Methotrexate—psoriatic arthritis	0.000192	0.00275	CcSEcCtD
Canagliflozin—Asthenia—Dexamethasone—psoriatic arthritis	0.000191	0.00273	CcSEcCtD
Canagliflozin—Asthenia—Betamethasone—psoriatic arthritis	0.000191	0.00273	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—psoriatic arthritis	0.00019	0.00271	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000189	0.00271	CcSEcCtD
Canagliflozin—Nausea—Prednisolone—psoriatic arthritis	0.000189	0.00271	CcSEcCtD
Canagliflozin—Pruritus—Betamethasone—psoriatic arthritis	0.000188	0.00269	CcSEcCtD
Canagliflozin—Pruritus—Dexamethasone—psoriatic arthritis	0.000188	0.00269	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—psoriatic arthritis	0.000188	0.00269	CcSEcCtD
Canagliflozin—Rash—Triamcinolone—psoriatic arthritis	0.000185	0.00264	CcSEcCtD
Canagliflozin—Dermatitis—Triamcinolone—psoriatic arthritis	0.000185	0.00264	CcSEcCtD
Canagliflozin—Rash—Methylprednisolone—psoriatic arthritis	0.000184	0.00264	CcSEcCtD
Canagliflozin—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000184	0.00263	CcSEcCtD
Canagliflozin—Urticaria—Prednisone—psoriatic arthritis	0.000184	0.00263	CcSEcCtD
Canagliflozin—Abdominal pain—Prednisone—psoriatic arthritis	0.000183	0.00262	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—psoriatic arthritis	0.000181	0.00259	CcSEcCtD
Canagliflozin—Dizziness—Dexamethasone—psoriatic arthritis	0.000176	0.00251	CcSEcCtD
Canagliflozin—Dizziness—Betamethasone—psoriatic arthritis	0.000176	0.00251	CcSEcCtD
Canagliflozin—Nausea—Triamcinolone—psoriatic arthritis	0.000174	0.00249	CcSEcCtD
Canagliflozin—Nausea—Methylprednisolone—psoriatic arthritis	0.000174	0.00248	CcSEcCtD
Canagliflozin—Hypersensitivity—Prednisone—psoriatic arthritis	0.000171	0.00244	CcSEcCtD
Canagliflozin—Rash—Betamethasone—psoriatic arthritis	0.000168	0.0024	CcSEcCtD
Canagliflozin—Rash—Dexamethasone—psoriatic arthritis	0.000168	0.0024	CcSEcCtD
Canagliflozin—Dermatitis—Dexamethasone—psoriatic arthritis	0.000168	0.00239	CcSEcCtD
Canagliflozin—Dermatitis—Betamethasone—psoriatic arthritis	0.000168	0.00239	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000167	0.00239	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—psoriatic arthritis	0.000167	0.00239	CcSEcCtD
Canagliflozin—Asthenia—Prednisone—psoriatic arthritis	0.000166	0.00238	CcSEcCtD
Canagliflozin—Pruritus—Prednisone—psoriatic arthritis	0.000164	0.00234	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000158	0.00226	CcSEcCtD
Canagliflozin—Nausea—Dexamethasone—psoriatic arthritis	0.000158	0.00226	CcSEcCtD
Canagliflozin—Nausea—Betamethasone—psoriatic arthritis	0.000158	0.00226	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—psoriatic arthritis	0.000154	0.0022	CcSEcCtD
Canagliflozin—Dizziness—Prednisone—psoriatic arthritis	0.000153	0.00219	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—psoriatic arthritis	0.000153	0.00219	CcSEcCtD
Canagliflozin—Rash—Prednisone—psoriatic arthritis	0.000146	0.00209	CcSEcCtD
Canagliflozin—Dermatitis—Prednisone—psoriatic arthritis	0.000146	0.00209	CcSEcCtD
Canagliflozin—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000143	0.00204	CcSEcCtD
Canagliflozin—Asthenia—Methotrexate—psoriatic arthritis	0.000139	0.00198	CcSEcCtD
Canagliflozin—Nausea—Prednisone—psoriatic arthritis	0.000138	0.00197	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—psoriatic arthritis	0.000137	0.00196	CcSEcCtD
Canagliflozin—Dizziness—Methotrexate—psoriatic arthritis	0.000128	0.00183	CcSEcCtD
Canagliflozin—Rash—Methotrexate—psoriatic arthritis	0.000122	0.00174	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—psoriatic arthritis	0.000122	0.00174	CcSEcCtD
Canagliflozin—Nausea—Methotrexate—psoriatic arthritis	0.000115	0.00164	CcSEcCtD
